tag:blogger.com,1999:blog-2741672436160438708.post4454082029597202456..comments2024-03-26T12:50:32.070-07:00Comments on Learning from and about cancer (chronic lymphocytic leukemia or CLL) by Dr. Brian Koffman: ASH 2012: Experimental Ibrutinib Promotes High Response Rate in LeukemiaBrian Koffmanhttp://www.blogger.com/profile/13250684684103918493noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-2741672436160438708.post-46141151914717086062012-12-18T09:50:05.277-08:002012-12-18T09:50:05.277-08:00I am hearing nothing but positives about Ibrutinib...I am hearing nothing but positives about Ibrutinib(PCI32765). 96% PFS after 2 years...WOW!!!!!...and that's 2 years and counting!!!!!<br />For younger patients I can see giving them something like FCR to get it knocked back then maintaining with the Ibrutinib. I hear that is already in the idea bank of the researchers but may be few years down the road. I am in the Ibrutinib resonate trial and have felt great taking this. If you are eligible for the trial I would consider getting in now as they still have slots available.<br /><br />http://clinicaltrials.gov/show/NCT01578707<br />Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-18710526438246135042012-12-17T12:44:11.322-08:002012-12-17T12:44:11.322-08:00Brian, I can't thank you enough for all the wo...Brian, I can't thank you enough for all the work you have done with your blog, it has been a tremendous source for me as well as others with CLL.<br /><br />Thank You David Tipton dx 2001, FCR 2004, relapse 2007, Rituxan Maint since 2009David Tiptonnoreply@blogger.com